Wednesday, July 8, 2026
🇺🇸 FDA

Drug profile · INN

phentermine hydrochloride

PHENTERMINE HYDROCHLORIDE

phentermine hydrochloride (PHENTERMINE HYDROCHLORIDE) is a norepinephrine transporter releasing agent. Associated with United Therapeutics Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 97
News articles 0
Drug details — phentermine hydrochloride
US status
approved
Class
—
Route
ORAL
Patents
20
Programs
97
Data quality
0.89
← All drugs Manufacturer profile Related patents Pipeline programs Drug news hub Event calendar

Quick answer

phentermine hydrochloride (PHENTERMINE HYDROCHLORIDE) is a norepinephrine transporter releasing agent. Associated with United Therapeutics Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN phentermine hydrochloride
Brand PHENTERMINE HYDROCHLORIDE
Mechanism Norepinephrine transporter releasing agent
Target Sodium-dependent noradrenaline transporter
Route ORAL
Formulation TABLET, ORALLY DISINTEGRATING
Originator United Therapeutics Europe Ltd

Mechanism of action

Norepinephrine transporter releasing agent

Primary target: Sodium-dependent noradrenaline transporter

Approval history

Authority Status Date
FDA approved —

Pipeline programs

Search pipeline Sponsor programs
  1. DTX401 Phase 3 · Ultragenyx UK · Glycogen Storage Disease Type IA
  2. RANOLAZINE, FLECARDIA Διάλυμα για ένεση/έχχυση Phase 3 · Anaxis Pharma · Restoration of sinus rhythm in patients with recent AF onset
  3. Tora-Dol /ml soluzione iniettabile for Patients scheduled for major su… Phase 3 · Telethon Foundation · Patients scheduled for major surgery for oncologic indicatio
  4. Acido Acetilsalicilico Teva Italia compresse... Phase 2 · Telethon Foundation · Patients scheduled for major surgery for oncologic indicatio
  5. CAPTURE Phase 2 · Telethon Foundation · Patients with advanced oncologic disease receiving active tr
  6. Enpatoran Placebo, Enpatoran Phase 2 · MSD Merck Sharp · Systemic lupus erythematosus (SLE) and cutaneous lupus eryth
  7. Enpatoran low dose Phase 2 · Serana Europe · Systemic Lupus Erythematosus
  8. MATRIx Phase 2 · Telethon Foundation · Traumatic Brain Injury

Related & competitor drugs

Browse all drugs
  1. amitriptyline hydrochloride Norepinephrine transporter inhibitor
  2. atomoxetine hydrochloride Norepinephrine transporter inhibitor
  3. desipramine hydrochloride Norepinephrine transporter inhibitor
  4. desvenlafaxine fumarate Norepinephrine transporter inhibitor
  5. doxepin hydrochloride Norepinephrine transporter inhibitor
  6. duloxetine hydrochloride Norepinephrine transporter inhibitor

Related patents

Browse patents United Therapeutics Europe Ltd patent hub

  1. US 12208148

    Dental restorative curable composition

    Expires Mon Jan 23 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12201658

    Viral gene therapy as treatment for cholesterol storage disease or disorder

    Expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12150445

    Method and composition for hypothermic storage of placental tissue

    Expires Mon Nov 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12128036

    Compositions and methods for storage stable ophthalmic drugs

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12060558

    Methods and compositions for treatment of cholesteryl ester storage disease

    Expires Mon Aug 08 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11219643

    Compositions for cellular restoration and methods of making and using same

    Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11185554

    Method of use of eritoran as a TLR4 antagonist for treatment of ebola and Marburg disease

    Expires Mon Nov 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11083708

    Pharmacological restoration of epithelial or endothelial barrier integrity by agents blocking EPAC/RAP1 signaling

    Expires Mon Aug 05 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10925975

    Acidic nanoparticles for restoration of autophagy

    Expires Mon Feb 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10918598

    On demand vesicle formation from vesicle precursors suitable for long-term storage

    Expires Mon Feb 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10897891

    Compositions and methods for prolonged cell storage

    Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10772911

    Cell free compositions for cellular restoration and methods of making and using same

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10667994

    Bioactive dental restorative material with remineralization properties

    Expires Mon May 28 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10322069

    Restorative resin compositions and methods of use

    Expires Mon Jun 13 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 9994814

    Method for cellular restoration

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 9993394

    Dental restorative composition

    Expires Mon Jun 07 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 8962709

    Resin systems for dental restorative materials and methods using same

    Expires Mon Feb 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 8727775

    Dimer acid-derived dimethacrylates and use in dental restorative compositions

    Expires Mon May 15 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 8628764

    Biocontrol of storage maladies of potatoes by bacterial antagonists produced in co-culture

    Expires Mon Jan 09 2034 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. EP 2511275

    Neuartige Piperidinyl-monocarboxylsäuren als S1P1 Rezeptoragonisten

    Expires Tue Oct 12 2032 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is phentermine hydrochloride?

phentermine hydrochloride (PHENTERMINE HYDROCHLORIDE) is a norepinephrine transporter releasing agent. Associated with United Therapeutics Europe Ltd. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for phentermine hydrochloride?

PHENTERMINE HYDROCHLORIDE is a marketed brand name for phentermine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of phentermine hydrochloride?

phentermine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.